Long term, open label and double blind placebo controlled studies in patients aged 20-8020 and patients aged 18-80 49 11 have shown that there are no particular safety concerns associated with 6-12 months treatment with Circadin® in all age groups. Efficacy was maintained without tolerance development. There is no warning against renewal of prescription following medical evaluation.
At the end of the treatment period the physician should reevaluate the need for treatment.
Posted in: Drug safety
